Merck & Co. Inc. diskutieren
Merck & Co. Inc.
WKN: A0YD8Q / Symbol: MRK / Name: Merck & Co / Aktie / Pharmazeutika / Large Cap /
127,86 €
0,08 %
Buy Merck & Co. Inc.
Sell Merck & Co. Inc.
Buy with target price 100.0
Merck & Co., Inc. (NYSE: MRK) is now covered by analysts at Mizuho. They set a "buy" rating and a $130.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Atlantic Securities from $122.00 to $127.00. They now have an "overweight" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $130.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $130.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its price target raised by analysts at Guggenheim from $123.00 to $124.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $122.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $122.00 price target on the stock, up previously from $117.00.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $132.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $115.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Neueste Beiträge
Canaccord_Genuity_Gr in Ultragenyx Pharmaceutical Inc. diskutieren